Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01579994

Recruitment Status : Active, not recruiting

First Posted : April 18, 2012

Last Update Posted : February 26, 2020

Sponsor:

Information provided by (Responsible Party):

Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	April 2021
Estimated Study Completion Date :	April 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wong KM, Noonan S, O'Bryant C, Jimeno A. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer. Drugs Today (Barc). 2015 Mar;51(3):161-70. doi: 10.1358/dot.2015.51.3.2294597. Review.

To Top